Improved glycemic control is associated with lower risk of complications related to metabolic syndrome
I don't see [GLP-1 agonists] as being any different than other medicine that we use to treat chronic conditions like atherosclerotic heart disease. While the data are not clear about the maintenance of CV benefits in those going off GLP-1 agents, data from mixed diet and lifestyle intervention studies, for example, do suggest that the cardiometabolic benefits of the lost weight may persist out to 5 years, even if some is regained
[PMID: 12812036] PubMed record related to this compound for laboratory literature review
This stepwise approach minimises the risk of bloating, diarrhoea or abdominal cramping
Starting at the lowest effective dose and increasing by the smallest available increment every two to four weeks gives your body maximum time to adapt
Nonetheless, Novo Nordisk and Eli Lilly have a formidable edge in production capacity and brand awareness